 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jan 26, 2010 |
| Title |
Multifactorial Approach to Predicting Resistance to Anthracyclines |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
PURPOSE: Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant TOP trial, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase IIα (TOP2A) and to develop a gene expression signature to identify those patients who do not benefit from anthracyclines.
METHODS: The TOP trial included 149 patients, of which 141 were evaluable for response prediction analyses. The primary endpoint was pathological complete response (pCR). TOP2A and gene expression profiles were evaluated using pre-epirubicin biopsies. Gene expression data from ER-negative samples of the EORTC 10994/BIG 00-01 and MDACC 2003-0321 neoadjuvant trials were used for validation purposes.
RESULTS: A pCR was obtained in 14% of the evaluable TOP patients. TOP2A amplification, but not protein overexpression, was significantly associated with pCR (p=0.001 and 0.22). We developed an “anthracycline-based score (A-Score)” that combines three signatures: a TOP2A gene signature and two previously published signatures related to tumor invasion and immune response. The A-Score was characterized by a high negative predictive value (NPV=0.98 [95% CI: 0.90-1.00]) overall, and in the HER2-negative and HER2-positive subpopulations. Its performance was independently confirmed in the anthracycline-based (FAC/FEC) arms of the two validation trials (BIG 00-01: 0.80 [0.61-0.92] and MDACC 2003-0321: 1.00 [0.80-1.00]).
CONCLUSION: Given its high NPV, the A-Score could become, if further validated, a useful clinical tool to identify those patients who do not benefit from anthracyclines and could therefore be spared the non-negligible side effects.
|
| |
|
| Overall design |
Predicting the efficacy of anthracyclines (epirubicin) in breast cancer (BC) patients (TOP trial)
120 microarray experiments from primary ER-negative breast tumors of anthracycline-treated patients.
No replicate, no reference sample.
|
| |
|
| Contributor(s) |
Desmedt C, Di Leo A, Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge4 S, Duhem C, Kains J, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret J, Qi Y, Symmans F, Pusztai L, D'Hondt V, Piccart-Gebhart M, Sotiriou C |
| Citation(s) |
21422418, 20098429, 20189874, 26484051 |
| |
| Submission date |
Jun 05, 2009 |
| Last update date |
Jun 06, 2022 |
| Contact name |
Benjamin Haibe-Kains |
| E-mail(s) |
benjamin.haibe.kains@utoronto.ca
|
| Phone |
+14165818626
|
| Organization name |
Princess Margaret Cancer Centre
|
| Department |
Princess Margaret Research
|
| Lab |
Bioinformatics and Computational Genomics
|
| Street address |
610 University Avenue
|
| City |
Toronto |
| State/province |
Ontario |
| ZIP/Postal code |
M5G 2M9 |
| Country |
Canada |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (120)
|
|
| Relations |
| BioProject |
PRJNA116011 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE16446_RAW.tar |
943.9 Mb |
(http)(custom) |
TAR (of CEL) |
| GSE16446_TOP_README.txt |
2.2 Kb |
(ftp)(http) |
TXT |
| GSE16446_TOP_demo.txt.gz |
2.5 Kb |
(ftp)(http) |
TXT |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...